Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance (U01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites applications for research projects to join the Small-Cell Lung Cancer (SCLC) Consortium. Goals of the SCLC Consortium pertinent to this FOA are: 1) to learn the mechanistic and biological underpinnings of SCLC formation, progression and heterogeneity; 2) to investigate how molecular vulnerabilities could be used to develop targeted agents or combinations; and 3) to understand clinical resistance to drug and radiation therapy and its rapid development.


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): November 12, 2019; March 11, 2020; November 12, 2020; March 11, 2021; November 12, 2021; March 11, 2022.

​PAR-19-361 Expiration Date March 12, 2022

Agency Website



Amount Description

Budgets are limited to $450,000 Direct Costs (excluding consortium F&A costs) per year. Budgets should reflect the actual needs of the proposed project and non-modular budgets require extensive justification.

The maximum project period is five years.

    Funding Type





    Environmental & Life Sciences
    Medical - Basic Science
    Medical - Clinical Science
    Medical - Translational

    External Deadline

    March 11, 2022